scholarly journals Impact of MHC Class I Chain-Related Gene a (MICA) Mismatch on Umbilical Cord Blood Hematopoietic Cell Transplantation

2018 ◽  
Vol 24 (3) ◽  
pp. S190
Author(s):  
Sagar S. Patel ◽  
Lisa Rybicki ◽  
Melissa Yurch ◽  
Dawn Thomas ◽  
Deepa Jagadeesh ◽  
...  
Keyword(s):  
Cord Blood ◽  
Cell Transplantation ◽  
Mhc Class I ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Class I ◽  
Related Gene

Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?

Blood ◽  
2003 ◽  
Vol 101 (11) ◽  
pp. 4233-4244 ◽  
Author(s):  
Satkiran S. Grewal ◽  
Juliet N. Barker ◽  
Stella M. Davies ◽  
John E. Wagner
Keyword(s):  
Cord Blood ◽  
Cell Transplantation ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Unrelated Donor

scholarly journals Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation

Life ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 102
Author(s):  
Hany Elmariah ◽  
Claudio G. Brunstein ◽  
Nelli Bejanyan
Keyword(s):  
Cord Blood ◽  
Cell Transplantation ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Immune Reconstitution ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Unrelated Donor ◽  
Allogeneic Hct

Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for a variety of hematologic diseases. However, this therapeutic platform is limited by an initial period when patients are profoundly immunocompromised. There is gradual immune recovery over time, that varies by transplant platform. Here, we review immune reconstitution after allogeneic HCT with a specific focus on two alternative donor platforms that have dramatically improved access to allogeneic HCT for patients who lack an HLA-matched related or unrelated donor: haploidentical and umbilical cord blood HCT. Despite challenges, interventions are available to mitigate the risks during the immunocompromised period including antimicrobial prophylaxis, modified immune suppression strategies, graft manipulation, and emerging adoptive cell therapies. Such interventions can improve the potential for long-term overall survival after allogeneic HCT.

Sign in / Sign up

Export Citation Format

Share Document